Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review

Published:2022-04 Issue: Volume:166 Page:205-220
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Juarez-Garcia Ariadna,Sharma Ruchika,Hunger Matthias,Kayaniyil Sheena,Penrod John R.,Chouaïd Christos

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference82 articles.

1. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges;Giroux Leprieur;Eur J Cancer,2017

2. Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer;Brahmer;N Engl J Med,2015

3. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer;Borghaei;N Engl J Med,2015

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

5. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer;BMC Cancer;2024-08-05

2. Pembrolizumab monotherapy survival benefits in metastatic non-small-cell lung cancer: a systematic review of real-world data;Discover Oncology;2024-07-24

3. Comparison of treatment outcome between first‐line combination immunotherapy (anti‐PD‐L1 or anti‐PD1) with or without chemotherapy and chemotherapy alone in advanced non‐small cell lung cancer patients in tertiary care hospital;Cancer Medicine;2024-07

4. Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer;Chinese Medical Journal;2024-01-22

5. Tumor Heterogeneity Confounds Lymphocyte Metrics in Diagnostic Lung Cancer Biopsies;Archives of Pathology & Laboratory Medicine;2023-06-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3